JAZZ - Jazz presents additional phase 2 data on zanidatamab for biliary tract cancer
2024-06-01 17:13:06 ET
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals: Cheap But Complicated
- Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
- Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug (update)
- J azz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript
- Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation